Naltrexone for the treatment of alcoholism: Clinical findings, mechanisms of action, and pharmacogenetics

CNS and Neurological Disorders - Drug Targets

Volumn 9, Issue 1, 2010, Pages 13-22

  Ray, Lara A ^a   Chin, Pauline F ^a   Miotto, Karen ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alcoholism; Mechanisms; Naltrexone; Neurobiology; Pharmacogenetics

Indexed keywords

6 BETA NALTREXOL; ALCOHOL; DRUG METABOLITE; NALTREXONE; OPIATE; OPIATE RECEPTOR; PLACEBO; UNCLASSIFIED DRUG;

ALCOHOLISM; ANXIETY; CLINICAL TRIAL; COGNITION; COMORBIDITY; CONTROLLED DRUG RELEASE; DEPRESSION; DIZZINESS; DOSE RESPONSE; DRUG ACTIVITY; DRUG ALCOHOL INTERACTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; GENETIC VARIABILITY; HEREDITY; HUMAN; LIVER FUNCTION TEST; LIVER TOXICITY; MENTAL DISEASE; NAUSEA; NERVOUSNESS; NONHUMAN; PATIENT COMPLIANCE; PHARMACOGENETICS; RECEPTOR UPREGULATION; REVIEW; SIDE EFFECT; SOCIAL PSYCHOLOGY; SUICIDAL IDEATION; SUICIDE ATTEMPT; SUPERSENSITIVITY; TREATMENT RESPONSE;

EID: 77949908684     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152710790966704     Document Type: Review

References (131)

1. Dawson, D.A.; Grant B.F.; Stinson F.S.; Chou, P.S.; Huang, B.; Ruan, W.J. Recovery from DSM-IV alcohol dependence: United States, 2001-2002. Addiction, 2005, 100, 281-292.
2. Grant, B.F.; Dawson, D.A.; Stinson, F.S.; Chou, S.P.; Dufour, M.C.; Pickering, R.P. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002. Drug Alcohol Depend., 2004, 74, 223-234.
3. Harwood, H. Updating Estimates of Economic Costs of Alcohol Abuse in the United States: Estimates, Updated Methods, and Data. National Institute on Alcohol Abuse and Alcoholism: Bethesda, MD, 2000.
4. McGinnis, J.M.; Foege, W.H. Actual causes of death in the United States. JAMA, 1993, 270, 2207-2212.
5. Center for Disease Control. Table 21. National vital statistics report. Center for Disease Control and Prevention: Atlanta, GA, 1999.
6. World Health Organization. The World Health Report, 2003.
7. Miller, W.R.; Walters, S.T.; Bennett, M.E. How effective is alcoholism treatment in the United States? J. Stud. Alcohol., 2001, 62, 211-220.
8. Fuller, R.K.; Hiller-Sturmhofel, S. Alcoholism treatment in the United States: an overview. Alcohol Res. Health, 1999, 23, 69-77.
9. Johnson, B.A. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem. Pharmacol., 2008, 75, 34-56.
10. Pettinati, H.M.; Rabinowitz, A.R. Choosing the right medication for the treatment of alcoholism. Curr. Psychiatry Rep., 2006, 8, 383-388.
11. O'Malley, S.S.; Jaffe, A.J.; Chang, G; Schottenfeld, R.S.; Meyer, R.E.; Rounsaville, B. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch. Gen. Psychiatry, 1992, 49, 881-887.
12. Volpicelli, J.R.; Alterman, A.I.; Hayashida, M.; O'Brien, C.P. Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry, 1992, 49, 876-880.
13. Litten, R.Z.; Allen, J; Fertig, J. Pharmacotherapies for alcohol problems: a review of research with focus on developments since 1991. Alcohol. Clin. Exp. Res., 1996, 20, 859-876.
14. Morris, P.L.; Hopwood, M.; Whelan, G.; Gardiner, J.; Drummond, E. Naltrexone for alcohol dependence: a randomized controlled trial. Addiction, 2001, 96, 1565-1573.
15. Chick, J.; Anton, R.; Checinski, K.; Croop, R.; Drummond DC, Farmer R.; Labriola, D.; Marshall, J.; Moncrieff, J.; Morgan, M.Y.; Peters, T.; Ritson, B. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol., 2000, 35, 587-593.
16. Anton, R.F.; Moak, D.H.; Waid, L.R.; Latham, P.K.; Malcolm, R.J.; Dias, J.K. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am. J. Psychiatry, 1999, 156, 1758-1764.
17. Zweben, A.; Pettinati, H.M.; Weiss, R.D.; Youngblood, M.; Cox, C.E.; Mattson, M.E.; Gorroochurn, P.; Ciraulo, D. Relationship between medication adherence and treatment outcomes: the COMBINE study. Alcohol. Clin. Exp. Res., 2008, 32, 1661-1669.
18. Rubio, G.; Manzanares, J.; Lopez-Munoz, F.; Alamo, C.; Ponce, G.; Jimenez-Arriero, M.A.; Palomo, T. Naltrexone improves outcome of a controlled drinking program. J. Subst. Abuse Treat., 2002, 23, 361-366.
19. Monti, P.M.; Rohsenow, D.J.; Swift, R.M.; Gulliver, S.B.; Colby, S.M.; Mueller, T.I.; Brown, R.A; Gordon, A.; Abrams, D.B.; Niaura, R.S.; Asher, M.K. Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol. Clin. Exp. Res., 2001, 25, 1634-1647.
20. Balldin, J.; Berglund, M.; Borg, S.; Mansson, M.; Bendtsen, P.; Franck, J.; Gustafsson, L.; Halldin, J.; Nilsson, L.H.; Stolt, G.; Willander, A. A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol. Clin. Exp. Res., 2003, 27, 1142-1149.
21. Kiefer, F.; Jahn, H.; Tarnaske, T.; Helwig, H.; Briken, P.; Holzbach, R.; Kämpf, P.; Stracke, R.; Baehr, M.; Naber, D.; Wiedemann, K. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch. Gen. Psychiatry, 2003, 60, 92-99.
22. Guardia, J.; Caso, C.; Arias, F.; Gual, A.; Sanahuja, J.; Ramirez, M.; Mengual, I.; Gonzalvo, B.; Segura, L.; Trujols, J.; Casas, M. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. Alcohol. Clin. Exp. Res., 2002, 26, 1381-1387.
23. Heinala, P.; Alho, H.; Kiianmaa, K.; Lonnqvist, J.; Kuoppasalmi, K.; Sinclair, J.D. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J. Clin. Psychopharmacol., 2001, 21, 287-292.
24. Latt, N.C.; Jurd, S.; Houseman, J.; Wutzke, S.E. Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. Med. J. Aust., 2002, 176, 530-534.
25. Davidson, D., Swift, R., Fitz, E. Naltrexone increases the latency to drink alcohol in social drinkers. Alcohol. Clin. Exp. Res., 1996, 20, 732-739.
26. Krystal, J.H.; Cramer, J.A.; Krol, W.F.; Kirk, G.F.; Rosenheck, R.A. Naltrexone in the treatment of alcohol dependence. N. Engl. J. Med., 2001, 345, 1734-1739.
27. Kranzler, H.R.; Modesto-Lowe, V.; Van Kirk, J. Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology, 2000, 22, 493-503.
28. Cohen J. Statistical Power Analysis for the Social Sciences. Erlbaum: Hillsdale, NJ, 1988.
29. McCaul, M.E.; Wand, G.S.; Eissenberg, T.; Rohde, C.A.; Cheskin, L.J. Naltrexone alters subjective and psychomotor responses to alcohol in heavy drinking subjects. Neuropsychopharmacology, 2000, 22, 480-492.
30. Krishnan-Sarin, S.; Krystal, J.H.; Shi, J.; Pittman, B.; O'Malley, S.S. Family history of alcoholism influences naltrexone-induced reduction in alcohol drinking. Biol. Psychiatry, 2007, 62, 694-697.
31. O'Malley, S.S.; Krishnan-Sarin, S.; McKee, S.A.; Leeman, R.F.; Cooney, N.L.; Meandzija, B.; Wu, R.; Makuch, R.W. Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. Int. J. Neuropsychopharmacol., 2009, 12, 589-597.
32. O'Malley, S.S.; Garbutt, J.C.; Gastfriend, D.R.; Dong, Q.; Kranzler, H.R. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. J. Clin. Psychopharmacol., 2007, 27, 507-512.
33. Ciraulo, D.A.; Dong, Q.; Silverman, B.L.; Gastfriend, D.R.; Pettinati, H.M. Early treatment response in alcohol dependence with extended-release naltrexone. J. Clin. Psychiatry, 2008, 69, 190-195.
34. Walsh, S.L.; Sullivan, J.T.; Preston, K.L.; Garner, J.E.; Bigelow, G.E. Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans. J. Pharmacol. Exp. Ther., 1996, 279, 524-538.
35. Lee, M.C.; Wagner, H.N. Jr.; Tanada, S.; Frost, J.J.; Bice, A.N.; Dannals, R.F. Duration of occupancy of opiate receptors by naltrexone. J. Nucl. Med., 1988, 29, 1207-1211.
36. Weerts, E.M.; Kim, Y.K.; Wand, G.S.; Dannals, R.F.; Lee, J.S.; Frost, J.J.; McCaul, M.E. Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects. Neuropsychopharmacology, 2008, 33, 653-665.
37. Roozen, H.G.; de Waart, R.; van den Brink, W. Efficacy and tolerability of naltrexone in the treatment of alcohol dependence: oral versus injectable delivery. Eur. Addict. Res., 2007, 13, 201-206.
38. King, A.C.; Volpicelli, J.R.; Gunduz, M.; O'Brien, C.P.; Kreek, M.J. Naltrexone biotransformation and incidence of subjective side effects: a preliminary study. Alcohol. Clin. Exp. Res., 1997, 21, 906-909.
39. Gonzalez, J.P.; Brogden, R.N. Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs, 1988, 35, 192-213.
40. Croop, R.S.; Faulkner, E.B.; Labriola, D.F. The Naltrexone Usage Study Group. the safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. Arch. Gen. Psychiatry, 1997, 54, 1130-1135.
41. Schneider, B. Substance use disorders and risk for completed suicide. Arch. Suicide Res., 2009, 13, 303-316.
42. Atkinson, R.L.; Berke, L.K.; Drake, C.R.; Bibbs, M.L.; Williams, F.L.; Kaiser, D.L. Effects of long-term therapy with naltrexone on body weight in obesity. Clin. Pharmacol. Ther., 1985, 38, 419-422.
43. Mitchell, J.E.; Morley, J.E.; Levine, A.S.; Hatsukami, D.; Gannon, M.; Pfohl, D. High-dose naltrexone therapy and dietary counseling for obesity. Biol. Psychiatry, 1987, 22, 35-42.
44. Malcolm, R.; O'Neil, P.M.; Sexauer, J.D.; Riddle, F.E.; Currey, H.S.; Counts, C. A controlled trial of naltrexone in obese humans. Int. J. Obes., 1985, 9, 347-353.
45. Brewer C.; Wong, V.S. Naltrexone: report of lack of hepatotoxicity in acute viral hepatitis, with a review of the literature. Addict. Biol., 2004, 9, 81-87.
46. Kranzler, H.R.; Stephenson, J.J.; Montejano, L.; Wang, S.; Gastfriend, D.R. Persistence with oral naltrexone for alcohol treatment: implications for health-care utilization. Addiction, 2008, 103, 1801-1808.
47. Feeney, G.F.; Connor, J.P.; Young, R.M.; Tucker, J.; Czajkowski, F. Adherence with naltrexone prescription advice in hospital outpatient alcohol rehabilitation programme. J. Clin. Pharm. Ther., 2001, 26, 73-79.
48. Baros, A.M.; Latham, P.K.; Moak, D.H.; Voronin, K.; Anton, R.F. What role does measuring medication compliance play in evaluating the efficacy of naltrexone? Alcohol. Clin. Exp. Res., 2007, 31, 596-603.
49. Cramer, J.; Rosenheck, R.; Kirk, G.; Krol, W.; Krystal, J. Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health, 2003, 6, 566-573.
50. Pettinati, H.M.; Gastfriend, D.R.; Dong Q.; Kranzler, H.R.; O'Malley, S.S. Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients. Alcohol. Clin. Exp. Res., 2009, 33, 350-356.
51. Kalivas, P.W.; Volkow, N.D. The neural basis of addiction: a pathology of motivation and choice. Am. J. Psychiatry, 2005, 162, 1403-1413.
52. Volkow, N.; Li, T.K. The neuroscience of addiction. Nat. Neurosci., 2005, 8, 1429-1430.
53. Littleton, J.; Little, H. Current concepts of ethanol dependence. Addiction, 1994, 89, 1397-1412.
54. Samson, H.H.; Tolliver, G.A.; Haraguchi, M.; Hodge, C.W. Alcohol self-administration: role of mesolimbic dopamine. Ann. NY Acad. Sci., 1992, 654, 242-253.
55. Weiss, F.; Lorang, M.T.; Bloom, F.E.; Koob, G.F. Oral alcohol self-administration stimulates dopamine release in the rat nucleus accumbens: genetic and motivational determinants. J. Pharmacol. Exp. Ther., 1993, 267, 250-258.
56. Erickson, C.K. Review of neurotransmitters and their role in alcoholism treatment. Alcohol Alcohol. Suppl., 1996, 1, 5-11.
57. Herz, A. Endogenous opioid systems and alcohol addiction. Psychopharmacology (Berl), 1997, 129, 99-111.
58. Kreek, M.J. Opiates, opioids and addiction. Mol. Psychiatry, 1996, 1, 232-254.
59. Bond, C.; LaForge, K.S.; Tian, M.; Melia, D.; Zhang, S.; Borg, L.; Gong, J.; Schluger, J.; Strong, J.A.; Leal, S.M.; Tischfield, J.A.; Kreek, M.J.; Yu, L. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc. Natl. Acad. Sci. USA, 1998, 95, 9608-9613.
60. Volpicelli, J.R. Alcohol abuse and alcoholism: an overview. J. Clin. Psychiatry, 2001, 62(Suppl. 20), 4-10.
61. Gianoulakis, C., Krishnan, B., Thavundayil, J. Enhanced sensitivity of pituitary beta-endorphin to ethanol in subjects at high risk of alcoholism. Arch. Gen. Psychiatry, 1996, 53, 250-257.
62. Kalivas, P.W.; Stewart, J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res. Rev., 1991, 16, 223-244.
63. Littleton, J.; Zieglgansberger, W. Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. Am. J. Addict., 2003, 12(Suppl 1), S3-S11.
64. Benjamin, D.; Grant, E.R.; Pohorecky, L.A. Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats. Brain Res., 1993, 621, 137-140.
65. Takemori, A.E.; Portoghese, P.S. Selective naltrexone-derived opioid receptor antagonists. Annu. Rev. Pharmacol. Toxicol., 1992, 32, 239-269.
66. Takemori, A.E.; Ho, B.Y.; Naeseth, J.S.; Portoghese, P.S. Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. J. Pharmacol. Exp. Ther., 1988, 246, 255-258.
67. McCaul, M.E.; Wand, G.S.; Stauffer, R.; Lee, S.M.; Rohde, C.A. Naltrexone dampens ethanol-induced cardiovascular and hypothalamic-pituitary-adrenal axis activation. Neuropsychopharmacology, 2001, 25, 537-547.
68. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands. Drug Discov. Today, 2004, 9, 641-651.
69. Gianoulakis, C.; de Waele, J.P. Genetics of alcoholism: role of the endogenous opioid system. Metab. Brain Dis., 1994, 9, 105-131.
70. Walker, B.M.; Koob, G.F. Regarding "Dynorphin is a downstream effector of striatal BDNF regulation of ethanol intake". FASEB J., 2008, 22, 2113.
71. Logrip, M.L.; Janak, P.H.; Ron, D. Dynorphin is a downstream effector of striatal BDNF regulation of ethanol intake. FASEB J., 2008, 22, 2393-2404.
72. Walker, B.M.; Koob, G.F. Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. Neuropsychopharmacology, 2008, 33, 643-652.
73. Hill, K.G.; Kiefer, S.W. Naltrexone treatment increases the aversiveness of alcohol for outbred rats. Alcohol. Clin. Exp. Res., 1997, 21, 637-641.
74. Ferraro, F.M., 3d.; Hill, K.G.; Kaczmarek, H.J.; Coonfield, D.L.; Kiefer, S.W. Naltrexone modifies the palatability of basic tastes and alcohol in outbred male rats. Alcohol, 2002, 27, 107-114.
75. Higley, A.E.; Kiefer, S.W. Delta receptor antagonism, ethanol taste reactivity, and ethanol consumption in outbred male rats. Alcohol, 2006, 40, 143-150.
76. Tiffany, S.T. A cognitive model of drug urges and drug-use behavior: role of automatic and nonautomatic processes. Psychol. Rev., 1990, 97, 147-168.
77. Marlatt, G.A.; Gordon, J.R. Relapse Prevention. Guilford: New York, 1985.
78. Monti, P.M.; Rohsenow, D.J.; Rubonis, A.V.; Niaura, R.S.; Sirota, A.D.; Colby, S.M.; Abrams, D.B. Alcohol cue reactivity: effects of detoxification and extended exposure. J. Stud. Alcohol, 1993, 54, 235-245.
79. Monti, P.M.; Rohsenow, D.J.; Rubonis, A.V.; Niaura, R.S.; Sirota, A.D.; Colby, S.M.; Goddard, P.; Abrams, D.B. Cue exposure with coping skills treatment for male alcoholics: a preliminary investigation. J. Consult. Clin. Psychol., 1993, 61, 1011-1019.
80. Ray, L.A.; Hutchison, K.E. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch. Gen. Psychiatry, 2007, 64, 1069-1077.
81. Drobes, D.J.; Anton, R.F.; Thomas, S.E.; Voronin, K. Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol. Clin. Exp. Res., 2004, 28, 1362-1370.
82. Swift, R.M.; Whelihan, W.; Kuznetsov, O.; Buongiorno, G.; Hsuing, H. Naltrexone-induced alterations in human ethanol intoxication. Am. J. Psychiatry, 1994, 151, 1463-1467.
83. Rosner, S.; Leucht, S.; Lehert, P.; Soyka, M. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J. Psychopharmacol., 2008, 22, 11-23.
84. Bouza, C.; Angeles, M.; Munoz, A.; Amate, J.M. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction, 2004, 99, 811-828.
85. Martin, C.S.; Earleywine, M.; Musty, R.E.; Perrine, M.W.; Swift, R.M. Development and validation of the biphasic alcohol effects scale. Alcohol. Clin. Exp. Res., 1993, 17, 140-146.
86. King, A.C.; Volpicelli, J.R.; Frazer, A.; O'Brien, C.P. Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology (Berl), 1997, 129, 15-22.
87. Ray, L.A.; Hutchison, K.E.; MacKillop, J.; Miranda, R.; Jr.; Audette, A.; Swift, R.; Monti, P.M. Effects of naltrexone during the descending limb of the blood alcohol curve. Am. J. Addict., 2008, 17, 257-264.
88. Earleywine, M. Confirming the factor structure of the anticipated biphasic alcohol effects scale. Alcohol. Clin. Exp. Res., 1994, 18, 861-866.
89. Kieres, A.K.; Hausknecht, K.A.; Farrar, A.M.; Acheson, A.; de Wit, H.; Richards, J.B. Effects of morphine and naltrexone on impulsive decision making in rats. Psychopharmacology (Berl), 2004, 173, 167-174.
90. Seu, E.; Lang, A.; Rivera, R.J.; Jentsch, J.D. Inhibition of the norepinephrine transporter improves behavioral flexibility in rats and monkeys. Psychopharmacology (Berl), 2009, 202, 505-519.
91. Mitchell, J.M.; Tavares, V.C.; Fields, H.L.; D'Esposito, M.; Boettiger, C.A. Endogenous opioid blockade and impulsive responding in alcoholics and healthy controls. Neuropsychopharmacology, 2007, 32, 439-449.
92. Anton, R.F.; Drobes, D.J.; Voronin, K.; Durazo-Avizu, R.; Moak, D. Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. Psychopharmacology (Berl), 2004, 173, 32-40.
93. Evans, W.E.; Johnson, J.A. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu. Rev. Genomics Hum. Genet., 2001, 2, 9-39.
94. Shastry, B.S. Pharmacogenetics and the concept of individualized medicine. Pharmacogenom. J., 2006, 6, 16-21.
95. Oslin, D.W.; Berrettini, W.; Kranzler, H.R.; Pettinati, H.; Gelernter, J; Volpicelli, J.R.; O'Brien, C.P. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology, 2003, 28, 1546-1552.
96. Goldman, D.; Oroszi, G.; O'Malley, S.; Anton R. COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms. J. Stud. Alcohol Suppl., 2005, Suppl 15, 56-64.
97. Zhang, Y.; Wang, D.; Johnson, A.D.; Papp, A.C.; Sadee, W. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J. Biol. Chem., 2005, 280, 32618-32624.
98. Schinka, J.A.; Town, T.; Abdullah, L; Crawford, F.C.; Ordorica, P.I.; Francis, E.; Hughes, P.; Graves, A.B.; Mortimer, J.A.; Mullan, M. A functional polymorphism within the mu-opioid receptor gene and risk for abuse of alcohol and other substances. Mol. Psychiatry, 2002, 7, 224-228.
99. Kranzler, H.R.; Gelernter, J.; O'Malley, S.; Hernandez-Avila, C.A.; Kaufman, D. Association of alcohol or other drug dependence with alleles of the mu opioid receptor gene (OPRM1). Alcohol. Clin. Exp. Res., 1998, 22, 1359-1362.
100. Town, T.; Abdullah, L.; Crawford, F.; Schinka, J.; Ordorica, P.I.; Francis, E.; Hughes, P.; Duara, R.; Mullan, M. Association of a functional mu-opioid receptor allele (+118A) with alcohol dependency. Am. J. Med. Genet., 1999, 88, 458-461.
101. Tan, E.C.; Tan, C.H.; Karupathivan, U.; Yap, E.P. Mu opioid receptor gene polymorphisms and heroin dependence in Asian populations. Neuroreport, 2003, 14, 569-572.
102. Bergen, A.W.; Kokoszka, J.; Peterson, R.; Long, J.C.; Virkkunen, M.; Linnoila, M.; Goldman, D. Mu opioid receptor gene variants: lack of association with alcohol dependence. Mol. Psychiatry, 1997, 2, 490-494.
103. Arias, A.; Feinn, R.; Kranzler, H.R. Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend., 2006, 83, 262-268.
104. Gelernter, J.; Kranzler, H.; Cubells, J. Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects. Mol. Psychiatry, 1999, 4, 476-483.
105. Crowley, J.J.; Oslin, D.W.; Patkar, A.A.; Gottheil, E.; DeMaria, P.A. Jr.; O'Brien, C.P.; Berrettini, W.H.; Grice, D.E. A genetic association study of the mu opioid receptor and severe opioid dependence. Psychiatr. Genet., 2003, 13, 169-173.
106. Franke, P.; Wang, T.; Nothen, M.M.; Knapp, M.; Neidt, H.; Albrecht, S.; Jahnes, E.; Propping, P.; Maier, W. Nonreplication of association between mu-opioid-receptor gene (OPRM1) A118G polymorphism and substance dependence. Am. J. Med. Genet., 2001, 105, 114-119.
107. Luo, X.; Kranzler, H.R; Zhao, H.; Gelernter, J. Haplotypes at the OPRM1 locus are associated with susceptibility to substance dependence in European-Americans. Am. J. Med. Genet. B Neuropsychiatr. Genet., 2003, 120B, 97-108.
108. Shi, J.; Hui, L.; Xu ,Y.; Wang, F.; Huang, W.; Hu, G. Sequence variations in the mu-opioid receptor gene (OPRM1) associated with human addiction to heroin. Hum Mutat., 2002, 19, 459-460.
109. Ducci, F.; Goldman, D. Genetic approaches to addiction: genes and alcohol. Addiction, 2008, 103, 1414-1428.
110. Ray, L.A.; MacKillop, J., Monti, P.M. Subjective responses to alcohol as endophenotypes: advancing genetics into etiological and treatment models of alcoholism. Subs. Use Misuse, 2010, in press.
111. Hines, L.M.; Ray, L.; Hutchison, K.; Tabakoff, B. Alcoholism: the dissection for endophenotypes. Dialogues Clin. Neurosci., 2005, 7, 153-163.
112. Anton, R.F.; Oroszi, G.; O'Malley, S.; Couper, D.; Swift, R.; Pettinati, H.; Goldman, D. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch. Gen. Psychiatry, 2008, 65, 135-144.
113. Wand, G.S.; McCaul, M.; Yang, X.; Reynolds, J.; Gotjen, D.; Lee, S.; Ali, A. The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology, 2002, 26, 106-114.
114. Hernandez-Avila, C.A.; Wand, G.; Luo, X.; Gelernter, J.; Kranzler, H.R. Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1). Am. J. Med. Genet. B Neuropsychiatr. Genet., 2003, 118B, 60-65.
115. Oroszi, G.; Anton, R.F.; O'Malley, S.; Swift, R.; Pettinati, H.; Couper, D., Yuan, Q.; Goldman, D. OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. Alcohol. Clin. Exp. Res., 2009, 33, 383-393.
116. Gelernter, J.; Gueorguieva, R.; Kranzler, H.R.; Zhang, H.; Cramer, J.; Rosenheck, R.; Krystal, J.H.; VA Cooperative Study #425 Study Group. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol. Clin. Exp. Res., 2007, 31, 555-563.
117. Garbutt, J.C.; Kranzler, H.R.; O'Malley, S.S.; Gastfriend, D.R.; Pettinati, H.M.; Silverman, B.L.; Loewy, J.W.; Ehrich, E.W.; Vivitrex Study Group. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA, 2005, 293, 1617-1625.
118. Tidey, J.W.; Monti, P.M.; Rohsenow, D.J.; Gwaltney, C.J.; Miranda, R. Jr.; McGeary, J.E.; MacKillop, J.; Swift, R.M.; Abrams, D.B.; Shiffman, S.; Paty, J.A. Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment. Alcohol. Clin. Exp. Res., 2008, 32, 58-66.
119. Rubio, G.; Ponce, G.; Rodriguez-Jimenez, R.; Jimenez-Arriero, M.A.; Hoenicka, J.; Palomo, T. Clinical predictors of response to naltrexone in alcoholic patients: who benefits most from treatment with naltrexone? Alcohol Alcohol., 2005, 40, 227-233.
120. Monterosso, J.R.; Flannery, B.A.; Pettinati, H.M.; Oslin, D.W.; Rukstalis, M.; O'Brien, C.P.; Volpicelli, J.R. Predicting treatment response to naltrexone: the influence of craving and family history. Am. J. Addict., 2001, 10, 258-268.
121. Rohsenow, D.J.; Miranda, R.; Jr.; McGeary, J.E; Monti, P.M. Family history and antisocial traits moderate naltrexone's effects on heavy drinking in alcoholics. Exp. Clin. Psychopharmacol., 2007, 15, 272-281.
122. Hasin, D.S.; Stinson, F.S.; Ogburn, E.; Grant, B.F. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch. Gen. Psychiatry, 2007, 64, 830-842.
123. Ralevski, E.; Ball, S.; Nich, C.; Limoncelli, D.; Petrakis I. The impact of personality disorders on alcohol-use outcomes in a pharmacotherapy trial for alcohol dependence and comorbid Axis I disorders. Am. J. Addict., 2007, 16, 443-449.
124. Petrakis, I.; Ralevski, E.; Nich, C.; Levinson, C.; Carroll, K.; Poling, J.; Rounsaville, B.; VA VISN I MIRECC Study Group. Naltrexone and disulfiram in patients with alcohol dependence and current depression. J. Clin. Psychopharmacol., 2007, 27, 160-165.
125. Petrakis, I.L.; Poling, J.; Levinson, C.; Nich, C.; Carroll, K.; Ralevski, E.; Rounsaville, B. Naltrexone and disulfiram in patients with alcohol dependence and comorbid post-traumatic stress disorder. Biol. Psychiatry, 2006, 60, 777-783.
126. Petrakis, I.L.; Nich, C.; Ralevski, E. Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophr. Bull., 2006, 32, 644-654.
127. Bogenschutz, M.P.; Scott Tonigan, J.; Pettinati, H.M. Effects of alcoholism typology on response to naltrexone in the COMBINE study. Alcohol. Clin. Exp. Res., 2009, 33, 10-18.
128. Leggio, L.; Kenna, G.A.; Fenton, M,; Bonenfant, E.; Swift, R.M. Typologies of alcohol dependence. From Jellinek to genetics and beyond. Neuropsychol. Rev., 2009, 19, 115-129.
129. O'Brien, C.P. Prospects for a genomic approach to the treatment of alcoholism. Arch. Gen. Psychiatry, 2008, 65, 132-133.
130. Tate, S.K.; Goldstein, D.B. Will tomorrow's medicines work for everyone? Nat. Genet., 2004, 36(11 Suppl), S34-S42.
131. Ray, L.A.; Oslin, D.W. Naltrexone for the treatment of alcohol dependence among African Americans: results from the COMBINE Study. Drug Alcohol Depend., 2009, 105, 256-258.